Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Actilyse: biological aspects].

M Samama1, B Cormier, J Conard

  • 1Laboratoire central d'hématologie, Hôtel-Dieu, Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|May 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ingestion and contact with polyethylene microplastics does not cause acute toxicity on marine zooplankton.

Journal of hazardous materials·2018
Same author

A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.

The British journal of dermatology·2018
Same author

Novel integrated 3D multidetector computed tomography and fluoroscopy fusion for left atrial appendage occlusion procedures.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2017
Same author

The Release of Tissue Factor Pathway Inhibitor and Platelet Factor 4 After Heparin Injection in Patients with Thrombocytosis.

Hematology (Amsterdam, Netherlands)·2016
Same author

Is there a justification for hysterectomy in patients with borderline ovarian tumors?

Surgical oncology·2016
Same author

[Venous thromboembolic risk during repatriation for medical reasons].

Journal des maladies vasculaires·2015
Same journal

Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Alterations in coronary circulation during aortic insufficiency in young subjects.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Cardio-esophageal auscultation.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Hypertensive accidents following the injection of acetylcholine.

Archives des maladies du coeur et des vaisseaux·2010
See all related articles

Recombinant tissue plasminogen activator (rtPA) effectively dissolves thrombi but can increase bleeding risk due to systemic fibrinolytic activity. Monitoring heparin is crucial to reduce re-occlusion after rtPA treatment.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Context:

  • Recombinant tissue plasminogen activator (rtPA) is a key thrombolytic agent.
  • Understanding rtPA's effects on coagulation and fibrinolysis is critical for patient safety.

Purpose:

  • To detail the alterations in coagulation and fibrinolysis induced by rtPA administration.
  • To differentiate thrombolytic efficacy from systemic fibrinolytic activity and associated bleeding risks.

Summary:

  • rtPA exhibits thrombolytic activity for thrombosis treatment and systemic fibrinolytic activity, decreasing fibrinogen and coagulation factors, which may increase bleeding risk, especially with invasive procedures.
  • Adequate plasma rtPA levels are necessary for efficacy. Fibrinogen decrease is variable but moderate in most patients (80%). Fibrin degradation product measurements are not reliable for diagnosing thrombus dissolution.

Related Experiment Videos

  • Careful heparin monitoring may reduce the risk of re-occlusion, though further research is required.

    • Impact:

    • Provides insights into rtPA's dual action, aiding clinicians in managing thrombolytic therapy.
    • Highlights the importance of monitoring coagulation parameters and heparin treatment to optimize rtPA use and minimize complications.
    • Emphasizes the need for further studies to refine rtPA administration protocols and reduce re-occlusion rates.